Government-Owned Inventions; Availability for Licensing, 29014-29015 [2015-12124]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
29014
Federal Register / Vol. 80, No. 97 / Wednesday, May 20, 2015 / Notices
Group; Radiation Therapeutics and Biology
Study Section.
Date: June 15–16, 2015.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Bo Hong, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6194, MSC 7804, Bethesda, MD
20892, 301–996–6208, hongb@csr.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Motor Function, Speech and
Rehabilitation Study Section.
Date: June 15, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Biao Tian, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3166, MSC 7848, Bethesda, MD
20892, 301–402–4411, tianbi@csr.nih.gov.
Name of Committee:Oncology 2—
Translational Clinical Integrated Review
Group; Cancer Biomarkers Study Section.
Date: June 17, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, 301–357–
9318, ngkl@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Cellular
Aspects of Diabetes and Obesity Study
Section.
Date: June 18, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Alexander D Politis, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3210,
MSC 7808, Bethesda, MD 20892, (301) 435–
1150, politisa@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Molecular
and Cellular Endocrinology Study Section.
Date: June 18, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: John Bleasdale, Ph.D.,
Scientific Review Officer, Center for
VerDate Sep<11>2014
23:50 May 19, 2015
Jkt 235001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6170,
MSC 7892, Bethesda, MD 20892, 301–435–
4514, bleasdaleje@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Synapses, Cytoskeleton and
Trafficking Study Section.
Date: June 18–19, 2015.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Alexandria, 480 King
Street, Alexandria, VA 22314.
Contact Person: Christine A Piggee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4186,
MSC 7850, Bethesda, MD 20892, 301–435–
0657, christine.piggee@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Traumatic
Brain Injury and Cerebrovascular Disorders.
Date: June 19, 2015.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Alexander Yakovlev,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5206,
MSC 7846, Bethesda, MD 20892–7846, 301–
435–1254, yakovleva@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 15, 2015.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–12242 Filed 5–19–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
SUMMARY:
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
A Novel Therapeutic Vector for
Hemoglobin Disorders
Description of Technology:
Investigators at the National Heart,
Lung, and Blood Institute have designed
a novel lentiviral vector as a potential
gene therapy for sickle cell anemia and
beta-thalassemia. The novel lentiviral
vector encodes the beta-globin gene in a
forward orientation and can produce 5–
10 fold higher viral titer and 4–10 fold
higher gene transfer efficiency to
hematopoietic stem cells than reverseoriented lentiviral vectors. In vivo
studies conducted in rhesus macaques
show beta-globin production after
transplantation with this novel
lentiviral vector. This technology could
provide an alternative therapy for
patients suffering from blood disorders
associated with beta-globin gene
mutations.
Potential Commercial Applications:
Gene therapy.
Competitive Advantages:
• Increased viral titers
• Increased transduction efficiency
• Large scale vector production
Development Stage:
• Early-stage
• In vitro data available
• In vivo data available (animal)
Inventors: Naoya Uchida and John F.
Tisdale (NHLBI).
Intellectual Property: HHS Reference
No. E–165–2014/0—U.S. Provisional
Application No. 62/048,881 filed
September 11, 2014.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D.; 301–495–
4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Denise Crooks at crooksd@
mail.nih.gov.
E:\FR\FM\20MYN1.SGM
20MYN1
Federal Register / Vol. 80, No. 97 / Wednesday, May 20, 2015 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
X-Clometer: Optimizing Portable
Radiography
Description of Technology: The
technology offered for licensing and
commercial development relates to a
method and apparatus that can
significantly improve the diagnostic
performance of portable chest (CXR) and
abdominal x-rays. This device quantifies
angulation of a patient to provide for a
better comparison of day-to-day
improvement.
The portable CXR is one of the most
commonly requested diagnostic medical
tests around the world. They are
performed nearly daily on some of the
sickest patients in hospitals.
Paradoxically, it is well documented
that portable radiography of the chest is
inconsistent and often inadequate.
An upright projection best evaluates
effusions, rules out free air, or detects
air-fluid levels. Optimally, the images
are obtained at similar angles each day,
even if not erect, to allow accurate
comparisons and assessment of change.
It is well documented that portable
radiography of the chest is inconsistent
and often inadequate. To achieve
optimal quality of the exam the
technologist attempts the most upright
projection; balanced with patient
condition and ability to achieve this
often impossible task.
Potential Commercial Applications:
Portable chest and abdominal x-rays
performed at patient’s hospital bedside.
Competitive Advantages:
• Currently, there is no quantitative
marker to indicate degree of the upright
position. Prior markers with small ball
bearings sinking to a small circle only
indicate if the patient is supine or not.
This technology introduces a simple
dynamic marker that can quantify the
angle at a glance for the radiologist to
best compare patient condition over
time. This device objectively quantifies
cassette angle with a ball bearing in a
cylindrical tube with markers to
indicate upright position in degrees.
• The technology improves
performance of CXR, allowing reliable
comparisons of patient condition over
time. Thus, better therapies can be
planned and unnecessary CT
(Computerized Tomography) can be
prevented.
• The technology improves care for
Intensive Care Unit patients, as
developing effusion and the need for
immediate drainage (as one of many
examples) can be more effectively
assessed with the present apparatus. A
widespread use of the device will save
lives through improved diagnosis and
comparison of effusions.
Development Stage:
VerDate Sep<11>2014
23:50 May 19, 2015
Jkt 235001
• A performance of a visual prototype
was demonstrated. The visual prototype
was imaged at 5 selected angles with a
chest phantom. Initial in-vitro results
demonstrate that angles can be
quantified to within 30 degrees.
• Improved prototypes with more
accuracy are currently being
manufactured for to patient use. In-vivo
studies will soon be underway to
validate clinical utility.
Inventors: Les R. Folio (CC) and Lucas
S. Folio
Publications:
1. Wandtke JC. Bedside chest radiography.
Radiology. 1994; 190:1–10. [PMID
8043058]
2. Pneumatikos I, Bouros D. Pleural effusions
in critically ill patients. Respiration.
2008; 76(3):241–248. [PMID 18824883]
3. Mattison LE, et al. Pleural effusions in the
medical ICU: Prevalence, causes, and
clinical implications. Chest. 1997
Apr;111(4):1018–1023. [PMID 9106583]
4. Fartoukh M, et al. Clinically documented
pleural effusions in medical ICU
patients: How useful is routine
thoracentesis? Chest. 2002
Jan;121(1):178–184. [PMID 11796448]
5. Bekemeyer WB, et al. Efficacy of chest
radiography in a respiratory intensive
care unit. A prospective study. Chest.
1985 Nov; 88(5): 691–696. [PMID:
4053711]
6. Tocino I. Chest imaging in intensive care
unit. Eur J Radiol 1996 Aug;23(1):46–57.
[PMID 8872073]
Patent Status: HHS Reference No. E–
036–2011/0—U.S. Patent Application
No. 14/005,024 filed September 13,
2013.
Licensing Contact: Tedd Fenn; 424–
297–0336; tedd.fenn@nih.gov
Collaborative Research Opportunity:
The NIH Clinical Center, Radiology and
Imaging Sciences, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize X-Clometer. Please
contact Ken Rose, Ph.D. at 240–276–
5509 or rosek@mail.nih.gov for more
information.
Dated: May 14, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–12124 Filed 5–19–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
29015
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Virology—A Study Section.
Date: June 8–9, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Long Beach Hotel, 111
East Ocean Blvd., Long Beach, CA 90802.
Contact Person: Kenneth M. Izumi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892, 301–496–
6980, izumikm@csr.nih.gov.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group;
Skeletal Muscle and Exercise Physiology
Study Section.
Date: June 10–11, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Historic Inns of Annapolis, 58 State
Circle, Annapolis, MD 21401.
Contact Person: Richard Ingraham, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4116,
MSC 7814, Bethesda, MD 20892, 301–496–
8551, ingrahamrh@mail.nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Cancer Etiology Study Section.
Date: June 11–12, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Svetlana Kotliarova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
Bethesda, MD 20892, 301–594–7945,
kotliars@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Palliative care and survivorship.
Date: June 11, 2015.
Time: 6:00 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Long Beach Hotel, 111
East Ocean Blvd., Long Beach, CA 90802.
Contact Person: Martha L. Hare, Ph.D., RN,
Scientific Review Officer, Center for
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 80, Number 97 (Wednesday, May 20, 2015)]
[Notices]
[Pages 29014-29015]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12124]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
A Novel Therapeutic Vector for Hemoglobin Disorders
Description of Technology: Investigators at the National Heart,
Lung, and Blood Institute have designed a novel lentiviral vector as a
potential gene therapy for sickle cell anemia and beta-thalassemia. The
novel lentiviral vector encodes the beta-globin gene in a forward
orientation and can produce 5-10 fold higher viral titer and 4-10 fold
higher gene transfer efficiency to hematopoietic stem cells than
reverse-oriented lentiviral vectors. In vivo studies conducted in
rhesus macaques show beta-globin production after transplantation with
this novel lentiviral vector. This technology could provide an
alternative therapy for patients suffering from blood disorders
associated with beta-globin gene mutations.
Potential Commercial Applications: Gene therapy.
Competitive Advantages:
Increased viral titers
Increased transduction efficiency
Large scale vector production
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Naoya Uchida and John F. Tisdale (NHLBI).
Intellectual Property: HHS Reference No. E-165-2014/0--U.S.
Provisional Application No. 62/048,881 filed September 11, 2014.
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D.; 301-495-4507;
thalhamc@mail.nih.gov.
Collaborative Research Opportunity: The National Heart, Lung and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize this technology. For collaboration
opportunities, please contact Denise Crooks at crooksd@mail.nih.gov.
[[Page 29015]]
X-Clometer: Optimizing Portable Radiography
Description of Technology: The technology offered for licensing and
commercial development relates to a method and apparatus that can
significantly improve the diagnostic performance of portable chest
(CXR) and abdominal x-rays. This device quantifies angulation of a
patient to provide for a better comparison of day-to-day improvement.
The portable CXR is one of the most commonly requested diagnostic
medical tests around the world. They are performed nearly daily on some
of the sickest patients in hospitals. Paradoxically, it is well
documented that portable radiography of the chest is inconsistent and
often inadequate.
An upright projection best evaluates effusions, rules out free air,
or detects air-fluid levels. Optimally, the images are obtained at
similar angles each day, even if not erect, to allow accurate
comparisons and assessment of change. It is well documented that
portable radiography of the chest is inconsistent and often inadequate.
To achieve optimal quality of the exam the technologist attempts the
most upright projection; balanced with patient condition and ability to
achieve this often impossible task.
Potential Commercial Applications: Portable chest and abdominal x-
rays performed at patient's hospital bedside.
Competitive Advantages:
Currently, there is no quantitative marker to indicate
degree of the upright position. Prior markers with small ball bearings
sinking to a small circle only indicate if the patient is supine or
not. This technology introduces a simple dynamic marker that can
quantify the angle at a glance for the radiologist to best compare
patient condition over time. This device objectively quantifies
cassette angle with a ball bearing in a cylindrical tube with markers
to indicate upright position in degrees.
The technology improves performance of CXR, allowing
reliable comparisons of patient condition over time. Thus, better
therapies can be planned and unnecessary CT (Computerized Tomography)
can be prevented.
The technology improves care for Intensive Care Unit
patients, as developing effusion and the need for immediate drainage
(as one of many examples) can be more effectively assessed with the
present apparatus. A widespread use of the device will save lives
through improved diagnosis and comparison of effusions.
Development Stage:
A performance of a visual prototype was demonstrated. The
visual prototype was imaged at 5 selected angles with a chest phantom.
Initial in-vitro results demonstrate that angles can be quantified to
within 30 degrees.
Improved prototypes with more accuracy are currently being
manufactured for to patient use. In-vivo studies will soon be underway
to validate clinical utility.
Inventors: Les R. Folio (CC) and Lucas S. Folio
Publications:
1. Wandtke JC. Bedside chest radiography. Radiology. 1994; 190:1-10.
[PMID 8043058]
2. Pneumatikos I, Bouros D. Pleural effusions in critically ill
patients. Respiration. 2008; 76(3):241-248. [PMID 18824883]
3. Mattison LE, et al. Pleural effusions in the medical ICU:
Prevalence, causes, and clinical implications. Chest. 1997
Apr;111(4):1018-1023. [PMID 9106583]
4. Fartoukh M, et al. Clinically documented pleural effusions in
medical ICU patients: How useful is routine thoracentesis? Chest.
2002 Jan;121(1):178-184. [PMID 11796448]
5. Bekemeyer WB, et al. Efficacy of chest radiography in a
respiratory intensive care unit. A prospective study. Chest. 1985
Nov; 88(5): 691-696. [PMID: 4053711]
6. Tocino I. Chest imaging in intensive care unit. Eur J Radiol 1996
Aug;23(1):46-57. [PMID 8872073]
Patent Status: HHS Reference No. E-036-2011/0--U.S. Patent
Application No. 14/005,024 filed September 13, 2013.
Licensing Contact: Tedd Fenn; 424-297-0336; tedd.fenn@nih.gov
Collaborative Research Opportunity: The NIH Clinical Center,
Radiology and Imaging Sciences, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize X-Clometer. Please contact Ken
Rose, Ph.D. at 240-276-5509 or rosek@mail.nih.gov for more information.
Dated: May 14, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-12124 Filed 5-19-15; 8:45 am]
BILLING CODE 4140-01-P
